State Street’s XLV offers lower fees and higher dividends, while Invesco’s IBBQ delivers stronger returns with elevated risk.
The State Street Health Care Select Sector SPDR ETF (XLV) undercuts the Invesco Nasdaq Biotechnology ETF (IBBQ) on costs, charging 0.08% versus 0.19%. XLV also yields 1.60% in dividends, nearly double IBBQ’s 0.79%.
Over the past year, IBBQ surged 45.5%, outpacing XLV’s broader healthcare exposure. However, IBBQ’s biotech focus introduces higher volatility, driven by FDA decisions and clinical trial outcomes. XLV’s diversification tempers swings but caps upside potential.
Investors face a trade-off between XLV’s stability and IBBQ’s growth-oriented, high-risk profile. Both funds serve distinct strategies within the healthcare sector.